Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Increase in Short Interest

Aadi Bioscience, Inc. (NASDAQ:AADI) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 547,500 shares, a growth of 136.0% from the December 31st total of 232,000 shares. Approximately 2.7% of the company’s stock are short sold. Based on an average daily volume of 322,600 shares, the short-interest ratio is currently 1.7 days.

Institutional Trading of Aadi Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in Aadi Bioscience in the 3rd quarter valued at approximately $32,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Aadi Bioscience in the 2nd quarter valued at approximately $37,000. Finally, BML Capital Management LLC acquired a new position in Aadi Bioscience in the 3rd quarter valued at approximately $4,120,000. 52.08% of the stock is owned by institutional investors and hedge funds.

Aadi Bioscience Stock Down 5.7 %

Shares of NASDAQ:AADI opened at $2.83 on Wednesday. Aadi Bioscience has a fifty-two week low of $1.21 and a fifty-two week high of $3.81. The firm has a 50-day simple moving average of $2.79 and a 200 day simple moving average of $2.15. The company has a market cap of $69.76 million, a PE ratio of -1.24 and a beta of 0.65.

Aadi Bioscience (NASDAQ:AADI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.46). The firm had revenue of $7.21 million during the quarter, compared to analyst estimates of $6.55 million. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. During the same period in the previous year, the business posted ($0.60) EPS. As a group, research analysts forecast that Aadi Bioscience will post -2.04 EPS for the current fiscal year.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.